Effect of timing of pegfilgrastim administration on absolute neutrophil count (ANC) trajectory among cancer patients (pts) receiving myelosuppressive chemotherapy (chemo).

被引：0
|
作者：
Li, Yanli
Klippel, Zandra Karina
Shih, Xiaolong
Wang, Hong
Reiner, Maureen
Page, John
机构：
[1] Amgen Inc, San Francisco, CA USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] SimulStat Inc, San Diego, CA USA
[4] TechData Serv Co LLC, King Of Prussia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20674
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CORRELATIONS BETWEEN LEUKOCYTE COUNT AND ABSOLUTE GRANULOCYTE COUNT IN PATIENTS RECEIVING CANCER-CHEMOTHERAPY
    BENSON, AB
    READ, TRC
    GOEBEL, SL
    KOELLER, JM
    TORMEY, DC
    CANCER, 1985, 56 (06) : 1350 - 1355
  • [22] Safety and efficacy of same-day administration of pegfilgrastim in patients (pts) receiving chemotherapy for gastrointestinal (GI) malignancies.
    Matera, Robert M.
    Relias, Valerie
    Saif, Wasif M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Baseline absolute neutrophil counts (ANC) and survival in second- line metastatic colorectal cancer (mCRC) patients (pts).
    Grothey, Axel
    Tabernero, Josep
    Mytelka, Daniel S.
    Li, Li
    Nasroulah, Federico
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Predictors of Febrile Neutropenia Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice
    Lyman, Gary H.
    Richert-Boe, Kathryn
    Lamerato, Lois
    Kaur, Manpreet
    Shah, Neel
    Lawrence, Tatiana
    Sundaresan, Devi
    Silvia, Amanda
    Hanau, Ahuva
    Weycker, Derek
    BLOOD, 2019, 134
  • [25] Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies
    Tatsuya Hayama
    Kenichi Sakurai
    Katsuhiro Miura
    Shinsaku Washinosu
    Shinya Tsuboi
    Akihiro Uchiike
    Yoshikazu Yoshida
    Masami Takei
    International Journal of Clinical Pharmacy, 2018, 40 : 997 - 1000
  • [26] Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies
    Hayama, Tatsuya
    Sakurai, Kenichi
    Miura, Katsuhiro
    Washinosu, Shinsaku
    Tsuboi, Shinya
    Uchiike, Akihiro
    Yoshida, Yoshikazu
    Takei, Masami
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (05) : 997 - 1000
  • [27] The effect of bone pain specific education vs general chemotherapy side -effect education on reported bone pain in patients (pts) with breast cancer receiving chemotherapy and pegfilgrastim
    Maxwell, C. L.
    Guinigundo, A. S.
    Vanni, L.
    Morrow, P. K.
    Reiner, M.
    Shih, A.
    Klippel, Z.
    Blanchard, E.
    CANCER RESEARCH, 2016, 76
  • [28] CORRELATIONS BETWEEN WHITE BLOOD-COUNT AND ABSOLUTE GRANULOCYTE COUNT IN PATIENTS RECEIVING CANCER-CHEMOTHERAPY
    BENSON, AB
    KOELLER, JM
    GOEBEL, SL
    ROSENBAUM, PR
    TORMEY, DC
    CLINICAL RESEARCH, 1983, 31 (04): : A741 - A741
  • [29] Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support
    Brugger, W.
    Bacon, P.
    Lawrinson, S.
    Romieu, G.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 (03) : 265 - 269
  • [30] THE EFFECT OF PEGFILGRASTIM ON COMPLETE BLOOD COUNT IN COLORECTAL CANCER PATIENTS TREATED WITH FOLFOX OR FOLFIRI CHEMOTHERAPY
    Kremer, V.
    Shapira, I.
    Leaf, A.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (03)
12345